Abstract
Evaluating the benefit of therapies for malignant mesothelioma is a quite difficult task. The difficulty lies in identifying patients who might have benefited from a given treatment but knowingly did not receive it. Unless these 'suitable' patients have been identified in advance of any treatment and the process of allocation to one treatment or another is without bias. This is best achieved by randomization and in our view, for relatively small trials with heterogeneous patients, that is best done with the additional step of minimization.
Keywords: Observational data, outcome, sample size, selection bias, statistical analysis.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents